Unique ID issued by UMIN | UMIN000009011 |
---|---|
Receipt number | R000010505 |
Scientific Title | JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study |
Date of disclosure of the study information | 2012/10/01 |
Last modified on | 2022/10/11 08:38:24 |
JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study
JIVROSG-0808 CDDP transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study
JIVROSG-0808(RADPLAT Japan, maxillary carcinoma-II) Cisplatinum (CDDP) transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study
JIVROSG-0808 CDDP transarterial chemoradiptherapy for patients with maxillary carcinoma, pahse II study
Japan |
maxillary carcinoma
Radiology |
Malignancy
NO
To evaluate the efficacy and safety of transarterial chemo-infusion therapy with using cisplatinum (CDDP) combined with radiation therapy.
Efficacy
local control rate
primary tumor response rate, frequency and grade of adverse event, 5 years survival rate and reurrence rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
Transarterial infusion of cisplatinum to feeding artery of maxillary carcinoma and irradiation to the same lesion.
20 | years-old | <= |
75 | years-old | >= |
Male and Female
Maxillaruy carcinoma which was pathologically diagnosed as squamous cell carcinoma.
Tumor stage is T3 or T4 based on UICC 7th edition.
Selective angiography of feeding artery is feasible.
Life expectancy is 8 weeks or more.
Performance status (ECOG) is 1, 2 or 3.
Function of major organs (e.g., cardiac function, renal function) are preserved.
Informed concent is obtained from the patient.
In status of myelosuppression.
Serious infectious lesion exists in head or neck region.
Serious complications exist(interstitial pneumonia, uncontrolable diabetes, heart failure, renal dysfunction, liver dysfunction, etc).
Viable double cancer or other malignant disease exists.
Patients who have past history of radiation therapy to head and neck region.
Patients who have allergic history for iodine contrast medium or platinums.
Patients who have serious mental disorder.
44
1st name | Yasuaki |
Middle name | |
Last name | Arai |
National cancer center hospital
Department of Diagnostic radiology
1040045
Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan
0335422511
sugasuga_shun@yahoo.co.jp
1st name | Norimitsu |
Middle name | |
Last name | Tanaka |
Kurume University
Department of Radiology
8300011
67, Asahimachi, Kurume City, Fukuoka
0942-31-7576
nori@med.kurume-u.ac.jp
National Cancer Center
National Cancer Center
Other
National Cancer Center
5-1-1, Tsukiji, Chuo-ku
03-3542-2511
sugasuga_shun@yahoo.co.jp
NO
北海道大学病院放射線科(吉田大介)
岩手医科大学放射線科(中里龍彦)
総合南東北病院血管内治療センター(今井茂樹)
宮城県立がんセンター放射線科(松本恒)
国立がんセンター放射線診断部(荒井保明)
奈良県立医科大学放射線科(中川裕之)
産業医科大学放射線科(興梠征典)
久留米大学放射線科(田中法瑞)
兵庫医科大学放射線科(石蔵礼一)
聖マリアンナ医科大学(滝澤謙治)
山形大学放射線科(鹿戸将史)
2012 | Year | 10 | Month | 01 | Day |
Unpublished
45
No longer recruiting
2012 | Year | 06 | Month | 15 | Day |
2019 | Year | 02 | Month | 04 | Day |
2012 | Year | 10 | Month | 01 | Day |
2022 | Year | 02 | Month | 09 | Day |
2022 | Year | 03 | Month | 09 | Day |
2012 | Year | 10 | Month | 01 | Day |
2022 | Year | 10 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010505
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |